Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.930
-1.020 (-34.58%)
At close: Jan 8, 2026, 4:00 PM EST
1.920
-0.010 (-0.52%)
After-hours: Jan 8, 2026, 7:02 PM EST
Acrivon Therapeutics Employees
As of December 31, 2024, Acrivon Therapeutics had 78 total employees, including 75 full-time and 3 part-time employees. The number of employees increased by 17 or 27.87% compared to the previous year.
Employees
78
Change (1Y)
17
Growth (1Y)
27.87%
Revenue / Employee
n/a
Profits / Employee
-$1,048,090
Market Cap
60.90M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 78 | 17 | 27.87% |
| Dec 31, 2023 | 61 | 17 | 38.64% |
| Dec 31, 2022 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACRV News
- 5 hours ago - Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls - Benzinga
- 11 hours ago - Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - GlobeNewsWire
- 2 days ago - Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - GlobeNewsWire
- 22 days ago - UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - GlobeNewsWire
- 2 months ago - Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 2 months ago - Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference - GlobeNewsWire
- 3 months ago - Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire